

Tom M A Wilkinson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8029263/publications.pdf>

Version: 2024-02-01

156
papers

10,768
citations

47006

47
h-index

33894

99
g-index

166
all docs

166
docs citations

166
times ranked

12652
citing authors

#	ARTICLE	IF	CITATIONS
1	Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. <i>Nature Medicine</i> , 2012, 18, 274-280.	30.7	882
2	Early Therapy Improves Outcomes of Exacerbations of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 1298-1303.	5.6	596
3	Airway and Systemic Inflammation and Decline in Lung Function in Patients With COPD. <i>Chest</i> , 2005, 128, 1995-2004.	0.8	404
4	Bronchiectasis, Exacerbation Indices, and Inflammation in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 400-407.	5.6	400
5	Use of Plasma Biomarkers at Exacerbation of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 867-874.	5.6	391
6	Long-term Erythromycin Therapy Is Associated with Decreased Chronic Obstructive Pulmonary Disease Exacerbations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 1139-1147.	5.6	384
7	A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 8800-8805.	7.1	384
8	Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 196-206.	10.7	370
9	Airway Bacterial Load and FEV ₁ Decline in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 1090-1095.	5.6	336
10	Inflammatory changes, recovery and recurrence at COPD exacerbation. <i>European Respiratory Journal</i> , 2007, 29, 527-534.	6.7	307
11	Systemic and Upper and Lower Airway Inflammation at Exacerbation of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 71-78.	5.6	304
12	Effect of Interactions Between Lower Airway Bacterial and Rhinoviral Infection in Exacerbations of COPD. <i>Chest</i> , 2006, 129, 317-324.	0.8	288
13	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. <i>Nature Medicine</i> , 2022, 28, 1031-1041.	30.7	281
14	Viral Load Drives Disease in Humans Experimentally Infected with Respiratory Syncytial Virus. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1305-1314.	5.6	276
15	Exacerbations and Time Spent Outdoors in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 171, 446-452.	5.6	267
16	British Thoracic Society guidelines for home oxygen use in adults: accredited by NICE. <i>Thorax</i> , 2015, 70, i1-i43.	5.6	236
17	Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. <i>Thorax</i> , 2018, 73, 422-430.	5.6	201
18	Longitudinal changes in the nature, severity and frequency of COPD exacerbations. <i>European Respiratory Journal</i> , 2003, 22, 931-936.	6.7	173

#	ARTICLE	IF	CITATIONS
19	Respiratory Syncytial Virus, Airway Inflammation, and FEV ₁ Decline in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 871-876.	5.6	169
20	Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. <i>European Respiratory Journal</i> , 2007, 30, 472-478.	6.7	166
21	A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD. <i>Thorax</i> , 2017, 72, 919-927.	5.6	152
22	Online versus face-to-face pulmonary rehabilitation for patients with chronic obstructive pulmonary disease: randomised controlled trial. <i>BMJ Open</i> , 2017, 7, e014580.	1.9	135
23	Primary Care Physicians' Challenges in Ordering Clinical Laboratory Tests and Interpreting Results. <i>Journal of the American Board of Family Medicine</i> , 2014, 27, 268-274.	1.5	118
24	Epidemiological relationships between the common cold and exacerbation frequency in COPD. <i>European Respiratory Journal</i> , 2005, 26, 846-852.	6.7	107
25	Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1488-1502.	5.6	107
26	Dysregulation of Antiviral Function of CD8 ⁺ T Cells in the Chronic Obstructive Pulmonary Disease Lung. Role of the PD-1/PD-L1 Axis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 642-651.	5.6	106
27	Relationships Among Bacteria, Upper Airway, Lower Airway, and Systemic Inflammation in COPD. <i>Chest</i> , 2005, 127, 1219.	0.8	101
28	Seasonal influenza vaccination in patients with COPD: a systematic literature review. <i>BMC Pulmonary Medicine</i> , 2017, 17, 79.	2.0	95
29	Steroid-induced Deficiency of Mucosal-associated Invariant T Cells in the Chronic Obstructive Pulmonary Disease Lung. Implications for Nontypeable <i>Haemophilus influenzae</i> Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1208-1218.	5.6	93
30	Relationship between pulmonary matrix metalloproteinases and quantitative CT markers of small airways disease and emphysema in COPD. <i>Thorax</i> , 2016, 71, 126-132.	5.6	82
31	Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. <i>Critical Care</i> , 2020, 24, 454.	5.8	81
32	Relationship between chronic nasal and respiratory symptoms in patients with COPD. <i>Respiratory Medicine</i> , 2003, 97, 909-914.	2.9	76
33	A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. <i>Npj Primary Care Respiratory Medicine</i> , 2016, 26, 16079.	2.6	75
34	Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations. <i>British Journal of Pharmacology</i> , 2021, 178, 626-635.	5.4	73
35	Effect of Preexisting Serum and Mucosal Antibody on Experimental Respiratory Syncytial Virus (RSV) Challenge and Infection of Adults. <i>Journal of Infectious Diseases</i> , 2015, 212, 1719-1725.	4.0	72
36	Inflammatory phenotyping predicts clinical outcome in COVID-19. <i>Respiratory Research</i> , 2020, 21, 245.	3.6	72

#	ARTICLE	IF	CITATIONS
37	Present and future utility of computed tomography scanning in the assessment and management of COPD. <i>European Respiratory Journal</i> , 2016, 48, 216-228.	6.7	70
38	Impact and associations of eosinophilic inflammation in COPD: analysis of the AERIS cohort. <i>European Respiratory Journal</i> , 2017, 50, 1700853.	6.7	68
39	Upper airway symptoms and quality of life in chronic obstructive pulmonary disease (COPD). <i>Respiratory Medicine</i> , 2004, 98, 767-770.	2.9	66
40	Seasonality, risk factors and burden of community-acquired pneumonia in COPD patients: a population database study using linked health care records. <i>International Journal of COPD</i> , 2017, Volume 12, 313-322.	2.3	64
41	ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 691.	1.6	62
42	Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 Interaction. <i>ACS Central Science</i> , 2022, 8, 527-545.	11.3	62
43	Impact of Chronic Obstructive Pulmonary Disease Exacerbations on Patients and Payers. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 218-221.	3.5	58
44	A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans. <i>Vaccine Journal</i> , 2015, 22, 828-835.	3.1	58
45	Palliative and end-of-life care conversations in COPD: a systematic literature review. <i>ERJ Open Research</i> , 2017, 3, 00068-2016.	2.6	56
46	Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals. <i>Antiviral Therapy</i> , 2013, 18, 785-791.	1.0	55
47	Human CD49a+ Lung Natural Killer Cell Cytotoxicity in Response to Influenza A Virus. <i>Frontiers in Immunology</i> , 2018, 9, 1671.	4.8	54
48	Virus-Specific Antibody Secreting Cell, Memory B-cell, and Sero-Antibody Responses in the Human Influenza Challenge Model. <i>Journal of Infectious Diseases</i> , 2014, 209, 1354-1361.	4.0	53
49	Noninvasive ventilation for COVID-19-associated acute hypoxaemic respiratory failure: experience from a single centre. <i>British Journal of Anaesthesia</i> , 2020, 125, e368-e371.	3.4	51
50	Dynamics of IFN- β Responses during Respiratory Viral Infection. Insights for Therapeutic Strategies. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 83-94.	5.6	50
51	Relationships Among Bacteria, Upper Airway, Lower Airway, and Systemic Inflammation in COPD. <i>Chest</i> , 2005, 127, 1219-1226.	0.8	49
52	IL-12 and IL-7 synergize to control mucosal-associated invariant T-cell cytotoxic responses to bacterial infection. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 2182-2195.e6.	2.9	49
53	Predicting and preventing hospital readmission for exacerbations of COPD. <i>ERJ Open Research</i> , 2020, 6, 00325-2019.	2.6	45
54	Viral Infection of Human Lung Macrophages Increases PDL1 Expression via IFN- β . <i>PLoS ONE</i> , 2015, 10, e0121527.	2.5	42

#	ARTICLE	IF	CITATIONS
55	Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial. <i>Vaccine</i> , 2019, 37, 6102-6111.	3.8	42
56	A Novel Lung Explant Model for the Ex Vivo Study of Efficacy and Mechanisms of Anti-Influenza Drugs. <i>Journal of Immunology</i> , 2015, 194, 6144-6154.	0.8	41
57	Guideline update: The British Thoracic Society Guidelines on home oxygen use in adults. <i>Thorax</i> , 2015, 70, 589-591.	5.6	41
58	Early COPD: current evidence for diagnosis and management. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662094212.	2.6	40
59	Respiratory viral infections in the elderly. <i>Therapeutic Advances in Respiratory Disease</i> , 2021, 15, 175346662199505.	2.6	39
60	Influenza vaccination for patients with chronic obstructive pulmonary disease: understanding immunogenicity, efficacy and effectiveness. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 349-367.	2.6	38
61	A randomised controlled feasibility trial of E-health application supported care vs usual care after exacerbation of COPD: the RESCUE trial. <i>Npj Digital Medicine</i> , 2020, 3, 145.	10.9	37
62	Building toolkits for COPD exacerbations: lessons from the past and present. <i>Thorax</i> , 2019, 74, 898-905.	5.6	34
63	Using Novel Computed Tomography Analysis to Describe the Contribution and Distribution of Emphysema and Small Airways Disease in Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2019, 16, 990-997.	3.2	34
64	Nasal symptoms, airway obstruction and disease severity in chronic obstructive pulmonary disease. <i>Clinical Physiology and Functional Imaging</i> , 2006, 26, 251-256.	1.2	31
65	Influenza A Virus Challenge Models in Cynomolgus Macaques Using the Authentic Inhaled Aerosol and Intra-Nasal Routes of Infection. <i>PLoS ONE</i> , 2016, 11, e0157887.	2.5	31
66	Relationships between Mucosal Antibodies, Non-Typeable Haemophilus influenzae (NTHi) Infection and Airway Inflammation in COPD. <i>PLoS ONE</i> , 2016, 11, e0167250.	2.5	30
67	Distinct emphysema subtypes defined by quantitative CT analysis are associated with specific pulmonary matrix metalloproteinases. <i>Respiratory Research</i> , 2016, 17, 92.	3.6	29
68	Research priorities for exacerbations of COPD. <i>Lancet Respiratory Medicine</i> , 2021, 9, 824-826.	10.7	28
69	Immune checkpoints in chronic obstructive pulmonary disease. <i>European Respiratory Review</i> , 2017, 26, 170045.	7.1	27
70	Influence of Hypoxia on the Epithelial-Pathogen Interactions in the Lung: Implications for Respiratory Disease. <i>Frontiers in Immunology</i> , 2021, 12, 653969.	4.8	27
71	The Role of Non-Typeable Haemophilus influenzae Biofilms in Chronic Obstructive Pulmonary Disease. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 720742.	3.9	26
72	Digital healthcare in COPD management: a narrative review on the advantages, pitfalls, and need for further research. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662210754.	2.6	26

#	ARTICLE	IF	CITATIONS
73	Novel expression of a functional trimeric fragment of human SP-A with efficacy in neutralisation of RSV. <i>Immunobiology</i> , 2017, 222, 111-118.	1.9	25
74	Relationship of CT-quantified emphysema, small airways disease and bronchial wall dimensions with physiological, inflammatory and infective measures in COPD. <i>Respiratory Research</i> , 2018, 19, 31.	3.6	25
75	Impact of radiologically stratified exacerbations: insights into pneumonia aetiology in COPD. <i>Respiratory Research</i> , 2018, 19, 143.	3.6	25
76	Interrelationships Among Small Airways Dysfunction, Neutrophilic Inflammation, and Exacerbation Frequency in COPD. <i>Chest</i> , 2021, 159, 1391-1399.	0.8	25
77	Extracellular Vesicles as Mediators of Cellular Cross Talk in the Lung Microenvironment. <i>Frontiers in Medicine</i> , 2020, 7, 326.	2.6	24
78	Evidence generation for the clinical impact of myCOPD in patients with mild, moderate and newly diagnosed COPD: a randomised controlled trial. <i>ERJ Open Research</i> , 2020, 6, 00460-2020.	2.6	23
79	Protocol for the Wessex AsThma CoHort of difficult asthma (WATCH): a pragmatic real-life longitudinal study of difficult asthma in the clinic. <i>BMC Pulmonary Medicine</i> , 2019, 19, 99.	2.0	22
80	Dysregulation of COVID-19 related gene expression in the COPD lung. <i>Respiratory Research</i> , 2021, 22, 164.	3.6	22
81	Human Lung Fibroblasts Present Bacterial Antigens to Autologous Lung Th Cells. <i>Journal of Immunology</i> , 2017, 198, 110-118.	0.8	21
82	Risk factors for persistent abnormality on chest radiographs at 12-weeks post hospitalisation with PCR confirmed COVID-19. <i>Respiratory Research</i> , 2021, 22, 157.	3.6	21
83	The Clinical Implications of Aspergillus Fumigatus Sensitization in Difficult-To-Treat Asthma Patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4254-4267.e10.	3.8	21
84	INHALED nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and statistical analysis plan for an investigator-initiated international metatrial of randomised studies. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3075-3091.	2.4	19
85	Shufeng Jiedu capsules for treating acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis. <i>BMC Complementary Medicine and Therapies</i> , 2020, 20, 151.	2.7	18
86	Exacerbation Of Chronic Obstructive Pulmonary Disease: Pan-Airway and Systemic Inflammatory Indices. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 481-482.	3.5	17
87	Acute Exacerbation and Respiratory InfectionS in COPD (AERIS): protocol for a prospective, observational cohort study. <i>BMJ Open</i> , 2014, 4, e004546.	1.9	17
88	IFN- β Influences Epithelial Antiviral Responses via Histone Methylation of the RIG-I Promoter. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2017, 57, 428-438.	2.9	17
89	Strategies for improving outcomes of COPD exacerbations. <i>International Journal of COPD</i> , 2006, 1, 335-342.	2.3	17
90	Drivers of year-to-year variation in exacerbation frequency of COPD: analysis of the AERIS cohort. <i>ERJ Open Research</i> , 2019, 5, 00248-2018.	2.6	16

#	ARTICLE	IF	CITATIONS
91	A specific proteinase 3 activity footprint in α 1-antitrypsin deficiency. ERJ Open Research, 2019, 5, 00095-2019.	2.6	16
92	Unravelling the mechanisms driving multimorbidity in COPD to develop holistic approaches to patient-centred care. European Respiratory Review, 2021, 30, 210041.	7.1	16
93	Non-typeable <i>Haemophilus influenzae</i> "Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial. Lancet Respiratory Medicine, 2022, 10, 435-446.	10.7	16
94	Viral Inhibition of Bacterial Phagocytosis by Human Macrophages: Redundant Role of CD36. PLoS ONE, 2016, 11, e0163889.	2.5	15
95	A time for everything and everything in its time – exploring the mechanisms underlying seasonality of COPD exacerbations. International Journal of COPD, 2018, Volume 13, 2739-2749.	2.3	15
96	Patients with Chronic Obstructive Pulmonary Disease harbour a variation of <i>Haemophilus</i> species. Scientific Reports, 2018, 8, 14734.	3.3	14
97	Patient perceived barriers to exercise and their clinical associations in difficult asthma. Asthma Research and Practice, 2020, 6, 5.	2.4	13
98	Reducing hospital admissions and improving the diagnosis of COPD in Southampton City: methods and results of a 12-month service improvement project. Npj Primary Care Respiratory Medicine, 2014, 24, 14035.	2.6	12
99	Defining a role for exercise training in the management of asthma. European Respiratory Review, 2020, 29, 190106.	7.1	12
100	Research Evaluation Alongside Clinical Treatment in COVID-19 (REACT COVID-19): an observational and biobanking study. BMJ Open, 2021, 11, e043012.	1.9	12
101	Systematic review of evidence for relationships between physiological and CT indices of small airways and clinical outcomes in COPD. Respiratory Medicine, 2018, 139, 117-125.	2.9	11
102	Immunopeptidomic analysis of influenza A virus infected human tissues identifies internal proteins as a rich source of HLA ligands. PLoS Pathogens, 2022, 18, e1009894.	4.7	11
103	Prediction of Chronic Obstructive Pulmonary Disease Exacerbation Events by Using Patient Self-reported Data in a Digital Health App: Statistical Evaluation and Machine Learning Approach. JMIR Medical Informatics, 2022, 10, e26499.	2.6	11
104	<scp>Nontypeable <i>Haemophilus influenzae</i></scp> infection of pulmonary macrophages drives neutrophilic inflammation in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2961-2973.	5.7	11
105	Biomarker identification using dynamic time warping analysis: a longitudinal cohort study of patients with COVID-19 in a UK tertiary hospital. BMJ Open, 2022, 12, e050331.	1.9	10
106	Biomarkers to guide the use of antibiotics for acute exacerbations of COPD (AECOPD): a systematic review and meta-analysis. BMC Pulmonary Medicine, 2022, 22, 194.	2.0	10
107	Seroprevalence of <i>Bordetella pertussis</i> Infection in Patients With Chronic Obstructive Pulmonary Disease in England: Analysis of the AERIS Cohort. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 341-348.	1.6	9
108	A qualitative study of GP, nurse and practice manager views on using targeted case-finding to identify patients with COPD in primary care. Npj Primary Care Respiratory Medicine, 2017, 27, 49.	2.6	8

#	ARTICLE	IF	CITATIONS
109	Comparisons of early and late presentation to hospital in COVID-19 patients. <i>Respirology</i> , 2021, 26, 204-205.	2.3	8
110	Sputum sample positivity for Haemophilus influenzae or Moraxella catarrhalis in acute exacerbations of chronic obstructive pulmonary disease: evaluation of association with positivity at earlier stable disease timepoints. <i>Respiratory Research</i> , 2021, 22, 67.	3.6	8
111	Specialist respiratory outreach: a case-finding initiative for identifying undiagnosed COPD in primary care. <i>Npj Primary Care Respiratory Medicine</i> , 2021, 31, 7.	2.6	8
112	Interrupting the Conversation: Implications for Crosstalk Between Viral and Bacterial Infections in the Asthmatic Airway. <i>Frontiers in Allergy</i> , 2021, 2, 738987.	2.8	8
113	Comparison of two methods of determining lung de-recruitment, using the forced oscillation technique. <i>European Journal of Applied Physiology</i> , 2018, 118, 2213-2224.	2.5	7
114	Dual RNASeq Reveals NTHi-Macrophage Transcriptomic Changes During Intracellular Persistence. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 723481.	3.9	7
115	Evidence Around the Impact of Pulmonary Rehabilitation and Exercise on Redox Status in COPD: A Systematic Review. <i>Frontiers in Sports and Active Living</i> , 2021, 3, 782590.	1.8	7
116	Large scale clinical trials: lessons from the COVID-19 pandemic. <i>BMJ Open Respiratory Research</i> , 2022, 9, e001226.	3.0	7
117	British Thoracic Society quality standards for home oxygen use in adults. <i>BMJ Open Respiratory Research</i> , 2017, 4, e000223.	3.0	6
118	Understanding disease mechanisms at the nanoscale: endothelial apoptosis and microparticles in COPD. <i>Thorax</i> , 2016, 71, 1078-1079.	5.6	5
119	Reply: The PD-1/PD-L1 Axis in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 644-645.	5.6	5
120	The emerging role of proteases in α 1-antitrypsin deficiency and beyond. <i>ERJ Open Research</i> , 2021, 7, 00494-2021.	2.6	5
121	Exercise Training Induces a Shift in Extracellular Redox Status with Alterations in the Pulmonary and Systemic Redox Landscape in Asthma. <i>Antioxidants</i> , 2021, 10, 1926.	5.1	5
122	The Role of Extracellular Vesicles as a Shared Disease Mechanism Contributing to Multimorbidity in Patients With COPD. <i>Frontiers in Immunology</i> , 2021, 12, 754004.	4.8	5
123	P238...A randomised controlled feasibility trial of an E-health platform supported care vs usual care after exacerbation of COPD. (RESCUE COPD). , 2018, , .		4
124	Primary care risk stratification in COPD using routinely collected data: a secondary data analysis. <i>Npj Primary Care Respiratory Medicine</i> , 2019, 29, 42.	2.6	4
125	The Detrimental Clinical Associations of Anxiety and Depression with Difficult Asthma Outcomes. <i>Journal of Personalized Medicine</i> , 2022, 12, 686.	2.5	4
126	Host-Pathogen Interactions during COPD Exacerbations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 323-325.	5.6	3

#	ARTICLE	IF	CITATIONS
127	Efeito do tiotropio na expectoraç�o e nos marcadores inflamat�rios s�ricos e exacerbaç�es da DPCO. Revista Portuguesa De Pneumologia, 2008, 14, 573-576.	0.7	3
128	From Disease Heterogeneity through Patient Endotype to "Microtype": The Future for Chronic Obstructive Pulmonary Disease Research?. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 686-687.	5.6	3
129	Asthma diagnosis in the community " time for a change?. Clinical and Experimental Allergy, 2014, 44, 1206-1209.	2.9	3
130	Are inhaled corticosteroids increasing the "load" for some patients with COPD?. European Respiratory Journal, 2017, 50, 1701848.	6.7	3
131	COPD exacerbations: transforming outcomes through research. Lancet Respiratory Medicine, the, 2018, 6, 172-174.	10.7	3
132	Development of flow cytometric opsonophagocytosis and antibody-mediated complement deposition assays for non-typeable Haemophilus influenzae. BMC Microbiology, 2018, 18, 167.	3.3	3
133	Relationship of CT densitometry to lung physiological parameters and health status in alpha-1 antitrypsin deficiency: initial report of a centralised database of the NIHR rare diseases translational research collaborative. BMJ Open, 2020, 10, e036045.	1.9	3
134	Case-finding for COPD clinic acceptability to patients in GPs across Hampshire: a qualitative study. Npj Primary Care Respiratory Medicine, 2021, 31, 4.	2.6	2
135	Effective nutrition support for patients with chronic obstructive pulmonary disease: managing malnutrition in primary care. British Journal of General Practice, 2021, 71, 427-428.	1.4	2
136	Clinician Perspectives on How to Hold Earlier Discussions About Palliative and End-of-Life Care With Chronic Obstructive Pulmonary Disease Patients. Journal of Hospice and Palliative Nursing, 2022, Publish Ahead of Print, .	0.9	2
137	Impact of bacterial strain acquisition in the lung of patients with COPD: the AERIS study. Infectious Diseases, 2022, 54, 784-793.	2.8	2
138	Accuracy of rapid point-of-care antibody test in patients with suspected or confirmed COVID-19. Journal of Infection, 2022, 84, 94-118.	3.3	1
139	Lung exosomal miRNAs discriminate between healthy ex-smokers and COPD. , 2019, , .		1
140	Distinguishing features of pneumonia and exacerbations in COPD. , 2015, , .		1
141	Fewer and smaller airways in COPD subjects measured by CT imaging. , 2019, , .		1
142	Early Therapy in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 292-292.	5.6	0
143	P120 Comparison of cellular inflammation and TLR expression profiles between healthy and COPD subjects. Thorax, 2011, 66, A116-A116.	5.6	0
144	P63 Assessment Of Regional Variability In Matrix Metalloproteinase Concentrations By Ct Informed Bronchoalveolar Lavage In Patients With Copd. Thorax, 2014, 69, A102-A102.	5.6	0

#	ARTICLE	IF	CITATIONS
145	Do lean markers relate to exacerbation rate in chronic obstructive pulmonary disease? Preliminary results from AERIS study. Proceedings of the Nutrition Society, 2015, 74, .	1.0	0
146	Variability of lean mass depletion in chronic obstructive pulmonary disease. Proceedings of the Nutrition Society, 2015, 74, .	1.0	0
147	98€...Palliative and advance care planning discussions with copd patients. , 2018, , .		0
148	Acquired immune responses to the seasonal trivalent influenza vaccination in COPD. Clinical and Experimental Immunology, 2019, 198, 71-82.	2.6	0
149	Sputum processing by mechanical dissociation: A rapid alternative to traditional sputum assessment approaches. Clinical Respiratory Journal, 2021, 15, 800-807.	1.6	0
150	Subcutaneous interferon beta-1a in COVID-19: raking the ashes of an intervention trial. Lancet Respiratory Medicine,the, 2021, 9, 1344-1345.	10.7	0
151	Bronchiectasis prevalence and relationship with clinical features in COPD. , 2015, , .		0
152	Identifying undiagnosed COPD through searches of UK routine primary care databases. , 2015, , .		0
153	Palliative and end of life care conversations in COPD - a systematic literature review. , 2017, , .		0
154	COPD patientsâ€™ preferences for palliative conversations with clinicians. , 2019, , .		0
155	Point-of-Care Inflammatory Phenotyping Predicts Clinical Outcome in COVID-19. SSRN Electronic Journal, 0, , .	0.4	0
156	Airway Epithelial JAK-STAT Gene Signatures Identify a Cluster of COPD Patients with Increased Blood Neutrophils. , 2022, , .		0